Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) moved up 3.52% and closed its last trading session at $2.06. This Medical Sector stock currently has the Market Capitalization of 307.1 Million. The Average Volume for the stock is measured as 1.02 Million. The Stock has a 52-Week High of $3.33 and 52-Week Low of $1.19 following the dates, it touched its 52-Week High on Sep 26, 2016 and 52-Week Low on May 10, 2016. Currently, the Return on Assets value for the trailing twelve months is -47.9% with the Return on Equity and Return on Investment of -53.5% and -37.3% respectively. This firm currently has YTD (year to date) performance of 37.33 Percent which is awesome. The Short Ratio for the stock is 7.78.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.32. The TTM operating margin is 0 percent.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) reports its Earnings on Thu 9 Mar (10 days ago). The estimated EPS for the current quarter is said to be $-0.11. Following Earnings result, share price were DOWN 15 times out of last 32 Qtrs. The stock has added about 7% since it reported its last earnings. The Closing price of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) at Last Earnings was $1.9 as compared to the previous closing price of $2.06. The Predicted Move on the 7th day after Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) will release its earnings at about 7%.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) beats earnings by 33%, The Stock Missed Earnings 3 times and has met earnings 3 times.
We will discuss the past Quarters Earnings below:
On 03/08/2017, Analysts were suspecting EPS of $-0.11/share where Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) reported its Actual EPS of $-0.11. Thus showing a Surprise of 0 percent. The Closing Price of the stock before earnings was $1.9 while on the Next day the stock closed its trading session at $1.88 with a percentage change of -1.05% from the price of 1.9 before Earnings. The Stock Closing Price on the 7th day of earnings was $1.83.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companys lead drug candidate is IMO-8400, which is in Phase I/II clinical trials for the treatment of Waldenströms Macroglobulinemia and diffuse large B-cell lymphoma, as well as in Phase II clinical trial for the treatment of dermatomyositis. Its drug candidates also comprise IMO-9200, a drug candidate in Phase I clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase I/II clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine products containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimers disease; an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test; a collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.